Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Receivables (2023 - 2025)

Historic Receivables for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $55.8 million.

  • Phathom Pharmaceuticals' Receivables rose 16500.57% to $55.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 16500.57%. This contributed to the annual value of $38.8 million for FY2024, which is 227000.61% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Receivables stood at $55.8 million, which was up 16500.57% from $51.3 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Receivables' 5-year high stood at $55.8 million during Q3 2025, with a 5-year trough of $1.6 million in Q4 2023.
  • Its 3-year average for Receivables is $27.5 million, with a median of $28.7 million in 2024.
  • Its Receivables has fluctuated over the past 5 years, first soared by 227000.61% in 2024, then surged by 16500.57% in 2025.
  • Phathom Pharmaceuticals' Receivables (Quarter) stood at $1.6 million in 2023, then skyrocketed by 2270.01% to $38.8 million in 2024, then surged by 43.8% to $55.8 million in 2025.
  • Its Receivables was $55.8 million in Q3 2025, compared to $51.3 million in Q2 2025 and $36.4 million in Q1 2025.